5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)—A potent FLAP inhibitor suitable for topical administration
- 1 August 2010
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (15), 4598-4601
- https://doi.org/10.1016/j.bmcl.2010.06.011
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Functional recognition of a distinct receptor preferential for leukotriene E4in mice lacking the cysteinyl leukotriene 1 and 2 receptorsProceedings of the National Academy of Sciences of the United States of America, 2008
- What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseasesTrends in Pharmacological Sciences, 2008
- The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptorThe EMBO Journal, 2006
- Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methodsBiochemical and Biophysical Research Communications, 2005
- Targeted Gene Disruption Reveals the Role of the Cysteinyl Leukotriene 2 Receptor in Increased Vascular Permeability and in Bleomycin-induced Pulmonary Fibrosis in MiceOnline Journal of Public Health Informatics, 2004
- Characterization of the Human Cysteinyl Leukotriene 2 ReceptorOnline Journal of Public Health Informatics, 2000
- Characterization of the human cysteinyl leukotriene CysLT1 receptorNature, 1999
- Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesisNature, 1990
- Production of Intraepidermal Microabscesses by Topical Application of Leukotriene B4Journal of Investigative Dermatology, 1984
- Local Effects of Synthetic Leukotrienes (LTC4, LTD4, and LTB4) in Human SkinJournal of Investigative Dermatology, 1983